Last updated 2026-07-20
- Raised $215M Series B led by Koch Disruptive Technologies, Sep 2021
- Acquired Nebion, Aug 2021
- Acquired Dropprint Genomics, Mar 2021
Total raised
$295.0M
Last: Undisclosed Round 2021-10
Stage
Series B
Founded
2018
Headcount
170
HQ
New York City, United States
Sector
Health Tech & Life Sciences
About
Immunai is an AI-driven biotechnology company that uses single-cell genomics and machine learning to comprehensively map and decode the human immune system. Their proprietary AMICA-OS platform integrates large-scale immune data with AI models to generate insights that can be used in drug development, biomarker identification, and clinical trial decision-making for immunology and oncology therapies. The company aims to accelerate the development of novel therapies by deeply understanding immune cell behavior and providing a comprehensive, end-to-end solution from data generation and curation to therapeutics development.
Funding history · 3 rounds · $295.0M total
2021-09
B Round
$215.0M
★ Koch Disruptive Technologies8VCICONGefen CapitalTalis CapitalPiedmont Venture CapitalAlexandria Venture Investments
2021-01
A Round
$60.0M
★ TLV Partners★ Meron Capital★ Gefen Capital★ Dexcel Pharma★ Viola Ventures★ Duquesne Family Office★ Catalio Capital Management★ Schusterman Family Investments
2020-04
Seed
$20.0M
★ TLV PartnersGefen CapitalViola Ventures
Headcount over time
From 3 (2020-05) to 190 (2026-03) · +187 (+6233%) · 55 points · source: Finder history + radar grounding
Q&A
- What is Immunai's primary focus?
- Immunai is developing a proprietary data set of multi-omic, immune-centric peripheral tissue analyses. Its platform is currently used to develop and refine cell therapies for neuroblastoma in conjunction with the Baylor College of Medicine.
- When was Immunai founded?
- Immunai was founded in January 2019.
- What was Immunai's most recent funding round?
- In October 2021, Immunai raised $215 million in a funding round led by Koch Disruptive Technologies.
- What was Immunai's second funding round?
- In February 2021, Immunai raised $60 million in a funding round.
- What was Immunai's first recorded funding round?
- In May 2020, Immunai raised $20 million in a funding round led by TLV Partners.
- What is the total amount of funding Immunai has raised to date?
- Immunai has raised a total of $295 million in funding.
- Which companies has Immunai acquired?
- Immunai acquired Dropprint Genomics in March 2021 and Nebion in August 2021.
- What is Immunai's primary sector?
- Immunai's primary sector is Health Tech & Life Sciences.
- Who are the co-founders of Immunai?
- The co-founders of Immunai are Noam Solomon (Co-founder & CEO), Luis Voloch (Co-founder & CTO), and Ansuman Satpathy (Scientific Co-Founder).
Team · 4
Noam Solomon
Founder · CEO & Co-Founder
Luis Voloch
Founder · Co-Founder
Ansuman Satpathy
Founder · Scientific Co-Founder
Danny Wells
Founder · Scientific Co-Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Business SoftwareIT, R&D & Data SolutionsData Analysis & Decision SupportHealth Tech & Life SciencesDigital HealthcareMedical Decision SupportPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Artificial IntelligenceDeep LearningMachine Learning
Target customers
Healthcare & Life SciencesHealthcareLaboratoriesProvidersLife SciencesPharmaceuticals
Business model
B2B
Tags
clinical-trialsimmunotherapyunicorn-2021digital-healthcarehospitalsimmunologydata-analyticsactionable-insightspharma-companiescancerautoimmune-diseasesartificial-intelligencemachine-learningdeep-learningcells
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | immunai.com |
|---|---|
| linkedin.com/company/53085519 | |
| YouTube | youtube.com/channel/UChTYZlcgoung0EZlsgq-G6g |
| Wikidata | wikidata.org/wiki/Q107519302 |
Identifiers & details
| Founded | 2018-12 |
|---|---|
| Employees (exact) | 170 |
| Offices | New York |
| Wikidata QID | Q107519302 |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| Nebion | 2021-08 | |
| Dropprint Genomics | 2021-03 |
Radar intelligence
Patents
| EPO | 4 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Web history (Wayback)
| Domain | immunai.com |
|---|
Wikidata
| QID | Q107519302 |
|---|
Certificate / subdomain footprint
| Subdomains | 12 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515981934 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2019-02-17 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 3 — violation (1), people (2) |
| Registered address | דרך אבא הלל 21 רמת גן |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-25 | עדכון הפרה |
| 2026-02-11 | עדכון דירקטורים-הסרת דירקטור |
| 2026-05-05 | עדכון בעלי תפקידים |